This paper will review clinical pharmacology studies on buprenorphine, a mixed opioid agonist-antagonist currently approved as a treatment for opioid dependence. The focus is on studies characterizing buprenorphine's pharmacodynamic actions, including its safety, abuse liability, withdrawal suppression and withdrawal precipitation capacity, physical dependence potential, cross-tolerance and duration of action as well as a review of the pharmacological profile of buprenorphine/naloxone combinations. The findings from these clinical pharmacology studies are synthesized and presented in a framework designed to (1) inform clinicians about the advantages and disadvantages of buprenorphine as an opioid maintenance agent, and (2) provide information about dosing procedures that may optimize the use of buprenorphine in the clinic.
|Journal||Drug and Alcohol Dependence|
|Issue number||2 SUPPL.|
|State||Published - May 21 2003|
Bibliographical noteFunding Information:
Financial support for preparation of this review was provided, in part, by grants from the National Institute on Drug Abuse (T32 DA07209 and P50 DA05273) and support from Reckitt-Benckiser.
- Clinical pharmacology
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)